The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: A randomized, placebo-controlled, multicenter study

44Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Poor control of hypertension or dyslipidemia may at least in part be due to these risk factors being treated in isolation. The Caduet in Untreated Subjects Population (CUSP) trial was an 8-week, randomized, double-blind, placebo-controlled trial evaluating the efficacy/safety of the combination of a calcium channel blocker (amlodipine besylate) and a statin (atorvastatin calcium) in a single-pill form (5/20 mg) plus therapeutic lifestyle changes (TLC) compared with placebo plus TLC in patients with comorbid hypertension and dyslipidemia without evidence of cardiovascular disease. At week 4, additional antihypertensive/ lipid-lowering medication was permitted. The primary end point was the proportion of patients in whom the dual goal of blood pressure (<140/90 mm Hg) and low-density lipoprotein cholesterol control (<100 mg/dL) was met at week 4. This dual goal attainment was significantly greater with amlodipine/atorvastatin plus TLC compared with placebo plus TLC at week 4 (47.6% vs 1.7%; P

Cite

CITATION STYLE

APA

Neutel, J. M., Bestermann, W. H., Dyess, E. M., Graff, A., Kursun, A., Sutradhar, S., & Yunis, C. (2009). The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: A randomized, placebo-controlled, multicenter study. Journal of Clinical Hypertension, 11(1), 22–30. https://doi.org/10.1111/j.1751-7176.2008.00058.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free